{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:21:13Z","timestamp":1777497673207,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The classification of pituitary neuroendocrine tumors (PitNETs), also known as pituitary adenomas, has progressed significantly since 2004. The PitNET lineage now serves as the foundation of the classification. We investigated the prognostic value of clinicopathological markers in a cohort of patients diagnosed with acromegaly and prolactinomas who underwent transsphenoidal tumor resection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 50 patients (45 patients with confirmed acromegaly and 5 with prolactinomas) in evidence at \u2018C. I. Parhon National Institute of Endocrinology (Pituitary and Neuroendocrine Pathology Department, Bucharest, Romania), who underwent tumor resection between 2010 and 2023, was recruited, with a median follow-up time of 7.02 years (IQR: 3\u201310). Surgical samples were stained for anterior pituitary hormones, ki-67 labeling index, CAM 5.2 expression, and the following transcription factors (TFs): steroidogenic factor (SF-1), T-box family member TBX19 (TPIT) and POU class 1 homeobox 1 (PIT-1). Additionally, somatostatin receptor 5 (SSTR 5) and 2 (SSTR 2) expression was evaluated in all patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Based on the 2022 WHO classification, the majority of cases were PIT-1 lineage tumors (n=40, 72.7%), followed by TPIT-lineage (n=4, 7.3%), and SF-1 lineage (n=3, 5.5%) and 14.5% (n=4) were classified as tumors with no distinct cell lineage (NDCL). In the multivariate Cox regression analysis, the postoperative GH value was independently associated with the outcome (HR 1.042, 95% CI 1.004\u20131.081, p=0.030), as well as the postoperative PRL value (HR 1.95% CI 1,1.001, p=0.019), the ki-67 labelling index (HR 2.43, 95% CI 1.109\u20135.330, p=0.026). Other factors associated as well with the success of the treatment were the postoperative tumor diameter (HR 1.038 95% CI 0.997\u20131.080, p=0.068) and the expression of SSTRs 2 and 5. Combining the four parameters, ki-67, SSTR 2, SSTR 5, GH, IGF-1 and the maximal tumor diameter (postoperative values), we established a prediction model with an AUC of 0.924 and relatively high sensitivity and specificity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A clear classification system that can guide clinical and neurosurgical management of patients with GH- and PRL-secreting PitNETs is not currently available, but certain clinicopathological factors can be used to predict patient prognosis. In our study, somatostatin receptor expression, ki-67, and postoperative values of GH and IGF-1, as well as the maximal postoperative tumor diameter, were the strongest predictors of outcome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1541514","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T09:36:43Z","timestamp":1744277803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Navigating prognostic strategies for GH- and PRL-secreting pituitary neuroendocrine tumors: key insights from a clinicopathological study"],"prefix":"10.3389","volume":"16","author":[{"given":"Roxana-Ioana","family":"Dumitriu-Stan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iulia-Florentina","family":"Burcea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Dobre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria Nicoleta","family":"Nastase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca Amalia","family":"Ceausu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalina Gabriela","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Raica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalina","family":"Poiana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.humpath.2020.12.001","article-title":"Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors","volume":"110","author":"Silva-Ortega","year":"2021","journal-title":"Hum Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s11102-022-01284-2","article-title":"Development of\u00a0a\u00a0cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumors","volume":"25","author":"Lenders","year":"2022","journal-title":"Pituitary"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0082-OA","article-title":"Steroidogenic factor 1, pit-1, and adrenocorticotropic hormone: a rational starting place for the immunohistochemical characterization of pituitary adenoma.","volume":"141","author":"McDonald","year":"2016","journal-title":"Arch Pathol Lab Med."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02655-0","article-title":"A standardized diagnostic approach to pituitary neuroendocrine tumors (PitNETs): a European pituitary pathology group (EPPG) proposal","volume":"475","author":"Villa","year":"2019","journal-title":"Virchows Arch"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-024-03849-x","article-title":"PIT-EASY survey: validation of the European Pituitary Pathology Group proposal for reporting pituitary neuroendocrine tumors","volume":"485","author":"Birtolo","year":"2024","journal-title":"Virchows Arch"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case\u2013control study of 410 patients with 8\u2009years postoperative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: A multicentric case-control study of 410 patients with 8 years postoperative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.807040","article-title":"Radiological knosp, revised-knosp, and hardy-wilson classifications for the prediction of surgical outcomes in the endoscopic endonasal surgery of pituitary adenomas: study of 228 cases","volume":"11","author":"Araujo-Castro","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.clinimag.2019.01.020","article-title":"Preoperative MRI predictors of hormonal remission status post pituitary adenoma resection","volume":"55","author":"Braileanu","year":"2019","journal-title":"Clin Imaging"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15048","article-title":"Clinicopathological features of growth hormone-producing pituitary adenomas and correlation with preoperative laboratory findings","volume":"41","author":"Burcea","year":"2021","journal-title":"Anticancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2670","article-title":"A consensus on criteria for cure of acromegaly","volume":"95","author":"Giustina","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/clinem\/dgaa859","article-title":"Discordant\u00a0GH and IGF-1 results in treated acromegaly: impact of GH cutoffs and mean values assessment","volume":"106","author":"Campana","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1256975","article-title":"Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study","author":"Romanisio","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970304)70:5<530::AID-IJC7>3.0.CO;2-Z","article-title":"Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: Comparison of mRNA analysis with receptor autoradiography","volume":"70","author":"Schaer","year":"1997","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000448429","article-title":"Somatostatin receptor expression in GH-secreting pituitary adenomas treated with long-acting somatostatin analogs in combination with pegvisomant","volume":"105","author":"Franck","year":"2017","journal-title":"Neuroendocrinology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","article-title":"Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form","volume":"19","author":"Obari","year":"2008","journal-title":"Endocr Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Acromegaly Consensus Group: Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0082-OA","article-title":"Steroidogenic factor 1, pit-1, and adrenocorticotropic hormone: A rational starting place for the immunohistochemical characterization of pituitary adenoma","volume":"141","author":"McDonald","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00001","article-title":"Multiple pituitary adenomas: A systematic review","volume":"7","author":"Budan","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198877","article-title":"Is\u00a0it\u00a0time to consider the expression of specific-pituitary hormone genes when typifying\u00a0pituitary tumours","volume":"13","author":"Garc\u00eda-Mart\u00ednez","year":"2018","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0328","article-title":"Somatostatin\u00a0receptor expression and clinical outcome of multilineage pituitary tumours expressing PIT1 and SF1","volume":"12","author":"Fookeerah","year":"2023","journal-title":"Endocr Connect"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1368944","article-title":"A clinicopathological study of nonfunctioning pituitary neuroendocrine tumors was performed via the World Health Organization 2022 classification","volume":"15","author":"Woo","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0901-5","article-title":"Advances and controversies in the classification and grading of pituitary tumors","volume":"42","author":"Laws","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133252","article-title":"Reappraising the role of trans-sphenoidal surgery in prolactin-secreting pituitary tumors","volume":"13","author":"Mattogno","year":"2021","journal-title":"Cancers"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2176\/nmc.52.563","article-title":"Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables","volume":"52","author":"Matsuyama","year":"2012","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40478-015-0229-8","article-title":"Histological criteria for atypical pituitary adenomas\u2014data from the German pituitary adenoma registry suggests modifications","volume":"3","author":"Miermeister","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11102-020-01096-2","article-title":"Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: A single center experience from a cohort of 131 patients with acromegaly","volume":"24","author":"Swanson","year":"2021","journal-title":"Pituitary"},{"key":"B30","article-title":"Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients","volume":"20","author":"Mazal","year":"2001","journal-title":"Clin Neuropathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-199307000-00003","article-title":"Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology","volume":"33","author":"Yamada","year":"1993","journal-title":"Neurosurgery"},{"key":"B32","doi-asserted-by":"publisher","first-page":"723432","DOI":"10.1155\/2013\/723432","article-title":"Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: classification according to hormone production and cytokeratin distribution","volume":"2013","author":"Mori","year":"2013","journal-title":"ISRN Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3390\/cancers15010267","article-title":"The prognostic-based approach in growth hormone-secreting pituitary neuroendocrine tumors (PitNET): tertiary reference center, single senior surgeon, and long-term follow-up","volume":"15","author":"Ferr\u00e9s","year":"2022","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-00982-8","article-title":"Predictive modeling for pituitary adenomas: Single center experience in 501 consecutive patients","volume":"22","author":"Pappy","year":"2019","journal-title":"Pituitary"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/BF01808879","article-title":"MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas","volume":"139","author":"Mizoue","year":"1997","journal-title":"Acta Neurochir (Wien)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2007.10.004","article-title":"Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas","volume":"39","author":"Gejman","year":"2008","journal-title":"Hum Pathol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab069","article-title":"Predictors for remission after transsphenoidal surgery in acromegaly: A dutch multicenter study","volume":"106","author":"Coopmans","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216162","article-title":"The value of ER\u221d in the prognosis of GH- and PRL-secreting pitNETs:\u00a0clinicopathological correlations","volume":"24","author":"Dumitriu-Stan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1038\/s41598-021-84606-x","article-title":"Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas","volume":"11","author":"Andereggen","year":"2021","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00006123-199601000-00024","article-title":"Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody","volume":"38","author":"Thapar","year":"1996","journal-title":"Neurosurgery"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly\u00a0predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1541514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T09:36:44Z","timestamp":1744277804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1541514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":42,"alternative-id":["10.3389\/fendo.2025.1541514"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1541514","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"article-number":"1541514"}}